Exhaustion marker profiling confirmed that T cells isolated from CLL patients prior to BTKi treatment had increased expression of PD-1 on CD4+ and CD8+ T cells compared with healthy donors (Fig. 1D, E) which significantly decreased in CD4 + T cells after long-term zanubrutinib treatment. Here, CD4 is linked to B-cell chronic lymphocytic leukemia.